Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases.
10.3724/zdxbyxb-2021-0063
- Author:
Lijuan MA
1
;
Shuang WU
1
;
Kai ZHANG
1
;
Mei TIAN
1
;
Hong ZHANG
1
Author Information
1. 4. College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, China.
- Publication Type:Review
- Keywords:
Cannabinoid type 1 receptor;
Mental disease;
Positron emission tomography;
Review;
Schizophrenia;
rative disease
- MeSH:
Cannabinoids;
Humans;
Mental Disorders/diagnostic imaging*;
Neurodegenerative Diseases/diagnostic imaging*;
Neurons;
Positron-Emission Tomography;
Receptor, Cannabinoid, CB1
- From:
Journal of Zhejiang University. Medical sciences
2021;50(5):666-673
- CountryChina
- Language:English
-
Abstract:
Cannabinoid type 1 receptor (CB1R), as the major member of the endocannabinoid system, is among the most abundant receptors expressed in the central nervous system. CB1R is mainly located on the axon terminals of presynaptic neurons and participate in the modulation of neuronal excitability and synaptic plasticity, playing an important role in the pathogenesis of various neuropsychiatric diseases. In recent years, the consistent development of CB1R radioligands and the maturity of molecular imaging techniques, particularly positron emission tomography (PET) may help to visualize the expression and distribution of CB1R in central nervous system . At present, CB1R PET imaging can effectively evaluate the changes of CB1R levels in neuropsychiatric diseases such as Huntington's disease and schizophrenia, and its correlation with the disease severity, therefore providing new insights for the diagnosis and treatment of neuropsychiatric diseases. This article reviews the application of CB1R PET imaging in Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, post-traumatic stress disorder, cannabis use disorder and depression.
